177Lu-EB-PSMA-617 also had higher absorbed doses in the red bone marrow and kidneys than 177Lu-PSMA-617 (0.0547?±?0.0062 vs. 0.0084?±?0.0057?mSv/MBq for red bone marrow, P?177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low imaging dose appears to be effective in ...
本共识由中国抗癌协会肿瘤核医学专业委员会和中国医师协会核医学医师分会共同发起 【微雅集公众号】•第1430期 相关链接:【文献分享】|177Lu-PSMA放射配体疗法的长期肾毒性研究 《中国核医学医师》微信公众号 主办单位 编审:李春林 关注...
幸而,近年核子医学的发展可能为患者带来新希望,其中之一是以放射性化学同位素「镏177」(Lu177)配合「前列腺特异性膜抗原」(PSMA)的放射核素治疗(下称「177Lu-PSMA-617疗法」)。 前列腺癌患者的PSMA可能高于常人100至1000倍,晚期前列腺癌患者的PSMA值...
Trial registration: Diagnosis of Adenoid Cystic Carcinoma on 68 Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 (NCT04801264, Registered 16 March 2021, retrospectively registered). URL of registry: https://clinicaltrials.gov/ct2/show/NCT04801264.Back...
dose in the tumor lesions were analyzed.SUV of Ga-PSMA-617 PET was moderately correlated with effective dose in main organs (r = 0.610 for Lu-PSMA-617, r = 0.743 for Lu-EB-PSMA-617, both P Pretherapeutic Ga-PSMA-617 PET may indicate the dosimetry of Lu-PSMA-617 and Lu-EB-PSMA-...
Group B (n = 10) was treated with a 2.12 +/- 0.19 GBq dose of 177Lu-EB-PSMA. Group C (n = 8) was treated with a 3.52 +/- 0.58 GBq dose of Lu-177-EB-PSMA. Eligible patients received up to 3 cycles of Lu-177-EB-PSMA therapy, at 8-wk intervals. Results: Because of ...
Lu-177Evans blueProstate-specific membrane antigen (PSMA)Metastatic castration-resistant prostate cancer (mCRPC)PurposeThis translational study is designed to assess the safety, dosimetry and therapeutic response to a single, low-dose of Lu-177-EB-PSMA-617 in comparison to Lu-177-PSMA-617 in ...
68Ga-PSMA-617 PET/CT18F-FDG PET/CTAdenoid cystic carcinoma177Lu-EB-PSMA-617URL of registry : https://clinicaltrials.gov/ct2/show/NCT04801264 .doi:10.1186/s13550-022-00922-xGuochang WangMengjiao ZhouJ. ZangYuanyuan JiangXiaohong Chen...
Conclusions Pretherapeutic Ga-68-PSMA-617 PET may indicate the dosimetry of Lu-177-PSMA-617 and Lu-177-EB-PSMA-617. Both the effective dose in main... Wang, JingnanZang, JieWang, HaoLiu, QingxingLi, FangLin, YansongHuo, LiJacobson, OritNiu, GangFan, XinrongZhu, ZhaohuiChen, Xiaoyuan...
首先,177Lu-PSMA-I&T与177Lu-PSMA-617疗法类似,两者的配体不同,PSMA-I&T有可能比PSMA-617更好;第二,我们开展的这项研究在亚洲人群中开展,同时纳入中国和韩国人群,PSMA-I&T的安全性非常好,特别是唾液腺损伤的发生率低于VISION研究;第...